Jiangsu Hengrui Medicine Co., Ltd. Jiangsu Hengrui Medicine Co., Ltd.

Jiangsu Hengrui Medicine Co., Ltd.

600276

Peringkat dalam Saham #544
Jiangsu Hengrui Medicine Co., Ltd. is a global biopharmaceutical firm engaged... Jiangsu Hengrui Medicine Co., Ltd. is a global biopharmaceutical firm engaged in the full spectrum of pharmaceutical operations, from the initial discovery and development of medications to their manufacturing and worldwide distribution. The company is actively advancing a substantial pipeline of drug candidates, which includes Apatinib, Pyrotinib, Mecapegfilgrastim, SHR3680, SHR3162, SHR9549, SHR2554, SHR1459, SHR-1309, SHR-A1201, Camrelizumab, Famitinib, SHR-1316, SHR-1501, SHR-1603, SHR-1701, SHR-1702, and SHR-A1403. These prospective treatments are aimed at a diverse range of medical conditions, primarily focusing on oncology, metabolic disorders, pain management, and autoimmune diseases, among others. The enterprise was founded in 1970 and maintains its corporate headquarters in Lianyungang, China.
Harga Saham
$6.89
Kapitalisasi Pasar
$43.94B
Perubahan (1 hari)
-2.91%
Perubahan (1 tahun)
-24.78%
Negara
CN
Perdagangan Jiangsu Hengrui Medicine Co., Ltd. (600276)

Kategori

Healthcare
Rasio P/S untuk Jiangsu Hengrui Medicine Co., Ltd. (600276)
Rasio P/S per October 2026 TTM: 9.37
Menurut laporan keuangan dan harga saham terbaru dari Jiangsu Hengrui Medicine Co., Ltd., rasio P/S saat ini (TTM) adalah 9.37. Pada akhir 2024, rasio P/S perusahaan adalah 10.39.
Riwayat rasio P/S untuk Jiangsu Hengrui Medicine Co., Ltd. dari 2001 hingga 2026
Rasio P/S pada akhir setiap tahun
Tahun Rasio P/S Mengubah
2026 (TTM) 9.37 -23.96%
2025 12.32 18.54%
2024 10.39 -17.13%
2023 12.54 8.76%
2022 11.53 -7.68%
2021 12.49 -41.32%
2020 21.29 28.72%
2019 16.54 47.69%
2018 11.20 -3.36%
2017 11.59 44.55%
2016 8.02 -6.62%
2015 8.58 63.97%
2014 5.24 -9.71%
2013 5.80 21.57%
2012 4.77 -5.76%
2011 5.06 -38.70%
2010 8.26 10.18%
2009 7.49 29.72%
2008 5.78 -34.42%
2007 8.81 78.87%
2006 4.92 420.22%
2005 0.95 14.31%
2004 0.83 -8.27%
2003 0.90 -28.02%
2002 1.25 -16.11%
2001 1.50 0.00%
Rasio P/S untuk perusahaan sejenis atau pesaing